- Report
- January 2025
- 50 Pages
Global
From €2663EUR$2,650USD£2,230GBP
- Report
- January 2025
- 50 Pages
Global
From €2663EUR$2,650USD£2,230GBP
- Report
- January 2025
- 50 Pages
Global
From €2663EUR$2,650USD£2,230GBP
- Report
- January 2025
- 50 Pages
Global
From €2663EUR$2,650USD£2,230GBP
- Report
- January 2025
- 50 Pages
Global
From €2663EUR$2,650USD£2,230GBP
- Report
- January 2025
- 50 Pages
Global
From €2663EUR$2,650USD£2,230GBP
- Report
- December 2023
- 132 Pages
Global
From €955EUR$950USD£799GBP
- Report
- July 2022
- 220 Pages
Global
From €3588EUR$3,570USD£3,004GBP
- Report
- October 2022
- 229 Pages
Global
From €3588EUR$3,570USD£3,004GBP
- Report
- September 2021
- 187 Pages
Global
From €3731EUR$3,712USD£3,123GBP
- Book
- July 2016
North America
The Schizophrenia Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of medications used to treat schizophrenia. Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to recognize what is real. Common symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior.
The Schizophrenia Drugs market is composed of a variety of companies, including large pharmaceutical companies, small biotech firms, and generic drug manufacturers. These companies develop and market medications that are used to treat schizophrenia, such as antipsychotics, antidepressants, and mood stabilizers. Many of these medications are available in both generic and brand-name forms.
Some of the major companies in the Schizophrenia Drugs market include Johnson & Johnson, Pfizer, Eli Lilly, Novartis, and AstraZeneca. These companies have developed a range of medications to treat schizophrenia, including Abilify, Seroquel, Zyprexa, and Risperdal. Show Less Read more